SequelSEC

AVITA Medical, Inc. RCEL

Surgical & Medical Instruments & Apparatus · CIK 0001762303 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$21.70M
Fiscal year ended 2026-06-30
Operating income
-$6.86M
Fiscal year ended 2026-06-30
Free cash flow
-$3.60M
Fiscal year ended 2026-06-30

AVITA Medical, Inc. (RCEL) reported revenue of $21.70M and net income of -$7.66M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from AVITA Medical, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

AVITA Medical, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$21.70M$19.25M$17.43M$17.06M$18.42M$18.51M$18.41M$19.55M$15.20M$11.10M
Cost of revenue$3.94M$3.52M$3.30M$3.19M$3.47M$2.83M$2.28M$3.19M$2.11M$1.51M
Gross profit$17.77M$15.73M$14.31M$13.88M$14.95M$15.68M$16.13M$16.36M$13.08M$9.59M
Operating income-$6.86M-$8.80M-$10.41M-$9.15M-$11.15M-$11.83M-$9.96M-$13.81M-$15.62M-$17.21M
Net income-$7.66M-$10.61M-$11.62M-$13.19M-$9.92M-$13.86M-$11.59M-$16.20M-$15.39M-$18.66M
Research & development$5.08M$5.63M$5.69M$3.75M$5.12M$6.28M$4.85M$5.43M$4.89M$5.19M
Weighted-average diluted sharesshares 30.75Mshares 30.54MUnavailableshares 28.39Mshares 26.37Mshares 26.25MUnavailableshares 25.98Mshares 25.76Mshares 25.64M
Pretax income-$7.63M-$10.62M-$11.64M-$13.17M-$9.92M-$13.85M-$11.57M-$16.23M-$15.36M-$18.63M
Income tax expense$33.00K-$11.00K-$17.00K$15.00K$4.00K$8.00K$19.00K-$28.00K$33.00K$30.00K
Diluted EPS$-0.25$-0.35Unavailable$-0.46$-0.38$-0.53Unavailable$-0.62$-0.60$-0.73
Selling, general & administrative$19.54M$18.90M$19.03M$19.28M$20.98M$21.22M$21.23M$24.73M$23.82M$21.60M
General & administrative$5.97M$6.06M$7.09M$7.23M$6.67M$6.39M$7.12M$9.59M$7.52M$8.96M
Selling & marketing$13.57M$12.84M$11.94M$12.05M$14.31M$14.83M$14.11M$15.14M$16.30M$12.64M

Balance

AVITA Medical, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$9.14M$8.31M$10.24M$15.42M$12.22M$14.87M$14.05M$18.64M$17.45M$16.95M
Total assets$47.78M$51.54M$56.39M$63.73M$58.13M$69.56M$79.71M$81.05M$87.83M$97.38M
Current assets$28.39M$31.65M$35.49M$41.37M$36.25M$47.97M$57.00M$63.92M$72.96M$85.99M
Total liabilities$75.62M$74.71M$73.04M$70.39M$70.98M$74.06M$74.97M$68.60M$63.51M$63.98M
Current liabilities$68.71M$66.67M$62.68M$61.83M$62.60M$22.96M$20.16M$17.14M$13.79M$11.86M
Total equity incl. NCI-$27.84M-$23.17M-$16.65M-$6.67M-$12.89M-$4.57M$4.50M$12.23M$23.92M$32.57M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$5.29M$6.12M$6.93M$7.24M$7.54M$8.40M$7.27M$6.23M$6.71M$7.17M
Accounts receivable$9.87M$9.88M$9.09M$9.01M$11.34M$9.10M$11.80M$10.29M$8.72M$11.80M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailable$0$0$42.22M$41.46M$42.24M$42.55M$40.99M$41.30M
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

AVITA Medical, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$3.50M-$10.07M-$5.44M-$5.22M-$10.23M-$10.31M-$8.04M-$7.21M-$12.78M-$20.86M
Capital expenditures$108.00K$19.00K-$674.00K$934.00K$524.00K$221.00K$1.61M$3.76M$2.65M$1.15M
Investing cash flow$3.89M$2.04M$11.00K-$5.34M$7.02M$10.77M$2.47M$7.39M$12.43M$15.07M
Financing cash flow$437.00K$6.10M$248.00K$13.77M$559.00K$363.00K$1.02M$1.01M$849.00K$631.00K
Net change in cash$830.00K-$1.93M-$5.18M$3.21M-$2.65M$820.00K-$4.59M$1.19M$501.00K-$5.17M
Stock-based compensation$1.99M$1.10M$1.37M$2.78M$2.68M$2.69M$2.80M$4.08M$4.03M$2.59M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$605.00K$627.00K$700.00K$574.00K$552.00K$521.00K$409.00K$310.00K$204.00K$203.00K

Derived

AVITA Medical, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$3.60M-$10.09MUnavailable-$6.15M-$10.75M-$10.53MUnavailable-$10.97M-$15.43M-$22.01M
Gross margin81.9%81.7%82.1%81.3%81.2%84.7%87.6%83.7%86.1%86.4%
Operating margin-31.6%-45.7%-59.7%-53.6%-60.5%-63.9%-54.1%-70.6%-102.8%-155.0%
FCF margin-16.6%-52.4%Unavailable-36.1%-58.4%-56.9%Unavailable-56.1%-101.6%-198.2%
SBC / revenue9.2%5.7%7.9%16.3%14.5%14.6%15.2%20.9%26.5%23.3%
Current ratio0.41x0.47x0.57x0.67x0.58x2.09x2.83x3.73x5.29x7.25x
Revenue YoY growth17.8%4.0%-5.3%-12.7%21.2%66.7%29.7%43.2%29.3%5.3%
Net margin-35.3%-55.1%-66.7%-77.3%-53.9%-74.9%-63.0%-82.9%-101.3%-168.0%
R&D / revenue23.4%29.2%32.6%22.0%27.8%33.9%26.4%27.8%32.2%46.8%
CapEx / revenue0.5%0.1%-3.9%5.5%2.8%1.2%8.8%19.2%17.5%10.3%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RCEL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-02-12View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2023-06-30

Difference 1228000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.